相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。TP53/p53-FBXO22-TFEB controls basal autophagy to govern hormesis
Narumi Suzuki et al.
AUTOPHAGY (2021)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
A. Bardia et al.
ANNALS OF ONCOLOGY (2021)
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: fi nal results from a phase I/II, single-arm, basket trial
K. Kalinsky et al.
ANNALS OF ONCOLOGY (2020)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Trophoblast cell surface antigen 2 (Trop-2) phosphorylation by protein kinase C α/δ (PKCα/δ) enhances cell motility
Yugo Mori et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1
Cai Zhang et al.
CLINICAL CANCER RESEARCH (2019)
TROP2 methylation and expression in tamoxifen-resistant breast cancer
Stephanie M. Zimmers et al.
CANCER CELL INTERNATIONAL (2018)
Trop-2 plasticity is controlled by epithelial-to-mesenchymal transition
Jan Remsik et al.
CARCINOGENESIS (2018)
A TFEB nuclear export signal integrates amino acid supply and glucose availability
Linxin Li et al.
NATURE COMMUNICATIONS (2018)
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Aditya Bardia et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
Rebecca Suk Heist et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The MiTF/TFE Family of Transcription Factors: Master Regulators of Organelle Signaling, Metabolism, and Stress Adaptation
Logan Slade et al.
MOLECULAR CANCER RESEARCH (2017)
Protein kinase C controls lysosome biogenesis independently of mTORC1
Yang Li et al.
NATURE CELL BIOLOGY (2016)
Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis
Ping Zeng et al.
SCIENTIFIC REPORTS (2016)
Interaction of BARD1 and HP1 Is Required for BRCA1 Retention at Sites of DNA Damage
Wenwen Wu et al.
CANCER RESEARCH (2015)
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Alexander N. Starodub et al.
CLINICAL CANCER RESEARCH (2015)
Glycogen Synthase Kinase-3 (GSK3) Inhibition Induces Prosurvival Autophagic Signals in Human Pancreatic Cancer Cells
Benoit Marchand et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Trop-2 Promotes Prostate Cancer Metastasis By Modulating β1 Integrin Functions
Marco Trerotola et al.
CANCER RESEARCH (2013)
Upregulation of Trop-2 quantitatively stimulates human cancer growth
M. Trerotola et al.
ONCOGENE (2013)
TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma
Jau-Chen Lin et al.
EMBO MOLECULAR MEDICINE (2012)
Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling
Tanya Stoyanova et al.
GENES & DEVELOPMENT (2012)
Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis
Marco Trerotola et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2012)
Identification of novel targets for breast cancer by exploring gene switches on a genome scale
Ming Wu et al.
BMC GENOMICS (2011)
Integrated Quantitative Analysis of the Phosphoproteome and Transcriptome in Tamoxifen-resistant Breast Cancer
Masaaki Oyama et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Phosphorylation by p38 MAPK as an alternative pathway for GSK3β inactivation
Tina M. Thornton et al.
SCIENCE (2008)
Use of an aggressive MCF-7 cell line variant, TMX2-28, to study cell invasion in breast cancer
Joseph M. Gozgit et al.
MOLECULAR CANCER RESEARCH (2006)
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
YV Kovtun et al.
CANCER RESEARCH (2006)
Erk associates with and primes GSK-3β for its inactivation resulting in upregulation of β-catenin
QQ Ding et al.
MOLECULAR CELL (2005)
Mass spectrometric and mutational analyses reveal lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase
H Nishikawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression
S Guaita et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
分享论文
